Shares of Bristol Myers Squibb Co. BMY rose 1.39% to $59.62 Friday, on what proved to be an all-around positive trading ...
The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly ...
The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...
On track to report initial data from Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 ---- IND-enabling studies ongoing for PM577 for ...
StockStory.org on MSN13h
Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q4 Earnings?Bristol-Myers Squibb has been a great trade, beating the S&P 500 by 13.7%. Its stock price has climbed to $58.28, ...
In this video, Arvind N. Dasari, MD, MS, discussed the results of the CheckMate 8HW trial in which nivolumab and ipilimumab were compared with nivolumab monotherapy for microsatellite instability-high ...
Bristol Myers Squibb Co. closed 3.76% short of its 52-week high of $61.10, which the company achieved on January 27th.
Mary-Claire King, a groundbreaking innovator in genetics, received The National Academy of Sciences' most prestigious metal.
Patient advocacy group Patients for Affordable Drugs (P4AD) yesterday filed its fourth amicus brief defending the Biden ...
Even as President Donald Trump wages a very public fight against diversity, equity and inclusion (DEI) initiatives in the ...
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) saw some unusual options trading on Tuesday. Traders acquired 46,473 call options on the company. This represents an increase of approximately 61% ...
Bristol-Myers Squibb saw an unexpected spike in options trading, with call options increasing by 61% compared to the average.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback